121 related articles for article (PubMed ID: 33576706)
1. Radiotherapy-induced glioblastoma: distinct differences in overall survival, tumor location, pMGMT methylation and primary tumor epidemiology in Hong Kong chinese patients.
Woo PYM; Lee JWY; Lam SW; Pu JKS; Chan DTM; Mak CHK; Ho JMK; Wong ST; Po YC; Lee MWY; Chan KY; Poon WS
Br J Neurosurg; 2024 Apr; 38(2):385-392. PubMed ID: 33576706
[TBL] [Abstract][Full Text] [Related]
2. Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Berger K; Turowski B; Felsberg J; Malzkorn B; Reifenberger G; Steiger HJ; Budach W; Haussmann J; Knipps J; Rapp M; Hänggi D; Sabel M; Mijderwijk HJ; Kamp MA
J Cancer Res Clin Oncol; 2021 Jan; 147(1):253-262. PubMed ID: 32748120
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of MGMT promoter methylation on the survival of TMZ treated
Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
[TBL] [Abstract][Full Text] [Related]
4. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
[TBL] [Abstract][Full Text] [Related]
5. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
[TBL] [Abstract][Full Text] [Related]
6. Association of molecular marker O(6)Methylguanine DNA methyltransferase and concomitant chemoradiotherapy with survival in Southern Chinese glioblastoma patients.
Chan DT; Kam MK; Ma BB; Ng SC; Pang JC; Lau CK; Siu DY; Ng BS; Zhu XL; Chen GG; Ng HK; Poon WS
Hong Kong Med J; 2011 Jun; 17(3):184-8. PubMed ID: 21636865
[TBL] [Abstract][Full Text] [Related]
7. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
[TBL] [Abstract][Full Text] [Related]
8. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T
Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
Biau J; Chautard E; De Schlichting E; Dupic G; Pereira B; Fogli A; Müller-Barthélémy M; Dalloz P; Khalil T; Dillies AF; Durando X; Godfraind C; Verrelle P
Radiat Oncol; 2017 Dec; 12(1):197. PubMed ID: 29212499
[TBL] [Abstract][Full Text] [Related]
10. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
11. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
[TBL] [Abstract][Full Text] [Related]
12. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
13. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
14. MGMT promoter methylation correlates with an overall survival benefit in Chinese high-grade glioblastoma patients treated with radiotherapy and alkylating agent-based chemotherapy: a single-institution study.
Shen D; Liu T; Lin Q; Lu X; Wang Q; Lin F; Mao W
PLoS One; 2014; 9(9):e107558. PubMed ID: 25211033
[TBL] [Abstract][Full Text] [Related]
15. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
Lombardi G; Pace A; Pasqualetti F; Rizzato S; Faedi M; Anghileri E; Nicolotto E; Bazzoli E; Bellu L; Villani V; Fabi A; Ferrazza P; Gurrieri L; Dall'Agata M; Eoli M; Della Puppa A; Pambuku A; D'Avella D; Berti F; Rudà R; Zagonel V
J Neurooncol; 2015 Nov; 125(2):359-67. PubMed ID: 26423801
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
17. Survival impact of incidental subventricular zone irradiation in IDH-wildtype glioblastoma.
Hallaert G; Pinson H; Van den Broecke C; Sweldens C; Van Roost D; Kalala JP; Boterberg T
Acta Oncol; 2021 May; 60(5):613-619. PubMed ID: 33689536
[TBL] [Abstract][Full Text] [Related]
18. The clinical characteristics and prognostic factors of multiple lesions in glioblastomas.
Tunthanathip T; Sangkhathat S; Tanvejsilp P; Kanjanapradit K
Clin Neurol Neurosurg; 2020 Aug; 195():105891. PubMed ID: 32480195
[TBL] [Abstract][Full Text] [Related]
19. Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
Mukherjee S; Wood J; Liaquat I; Stapleton SR; Martin AJ
Clin Neurol Neurosurg; 2020 Jan; 188():105568. PubMed ID: 31739155
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.
Hsieh SY; Chan DT; Kam MK; Loong HH; Tsang WK; Poon DM; Ng SC; Poon WS
Hong Kong Med J; 2017 Dec; 23(6):594-8. PubMed ID: 28798282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]